期刊文献+

急性脑梗死患者外周血白细胞介素-2水平测定

Measurement of interleukin-2 serum level in the patients with acute cerebral infarction
暂未订购
导出
摘要 目的 研究脑梗死急性期外周血白细胞介素 - 2水平的变化及意义。方法 采用放射免疫法测定脑梗死患者发病后 4 8h内与 2周后血清白细胞介素 - 2水平 ,同时与对照组比较。结果 急性脑梗死患者外周血白细胞介素 - 2水平明显低于对照组。结论 急性脑梗死患者白细胞介素 - 2水平低下提示免疫功能低下 ,易并发感染 。 Objective To study the change and significance of serum level of interleukin-2 in the patients with acute cerebral infarction.Method With radioimmunoassay to detect serum level of interleukin-2 in the patients with acute cerebral infarction within 48 hours,in two weeks after onset,compared with the control group.Result Serum level of interleukin-2 in the patients with acute cerebral infarction reduced obviously. Conclusions Reduced interleukin-2 in patients with acute cerebral infarction suggests immunodeficiency,state of being infected easily,and disadvantageous restore of pathological impair.
出处 《铁道医学》 2000年第2期79-80,共2页 Railway Medical Journal
关键词 急性脑梗塞 细胞因子 白细胞介素2 acute cerebral infarction cytokine interleukin-2
  • 相关文献

参考文献7

二级参考文献52

  • 1Berrada N , Delaloge S, Andre F. Treatment of triple-negative metastaticbreast cancer:toward individualized targeted treatments or chemosensitiza-tion?[J]. Ann Oncol,2010,21 Suppl 7:vii30-vii35.
  • 2Kim HR, Jung KH, Im SA, et al. Multicentre phase II trial of bevacizumabcombined with docetaxel-carboplatin for the neoadjuvant treatment oftriple-negative breast cancer (KCSG BR-0905) [J]. Ann Oncol,2013,24(6):1485-1490.
  • 3Silver DP , Richardson AL, Eklund AC , et al. Efficacy of neoadjuvantCisplatin in triple-negative breast cancer[J]. J Clin Oncol,2010,28(7):1145-1153.
  • 4Venkitaraman R. Triple - negative / basal - like breast cancer : clinical,pathologicand molecular features[J]. Expert Rev Anticancer Ther,2010,10(2):199-207.
  • 5Isakoff SJ, Mayer EL, He L, et, al. TBCRC009 : a Multicenter phase I clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015,33 (17) : 1902-1909.
  • 6O'Shaughnessy J, Schwartzberg L, Danso MA , et al. Phase III study ofiniparib plus gemcitabine and carboplatin versus gemcitabine andcarboplatin in patients with metastatic triple-negative breast cancer [Jj.J Clin Oncol, 2014,32( 34) : 3840-3847.
  • 7Biganzoli L,Coleman R,Minisini A , et al. A joined analysis of twoEuropean Organization for the Research and Treatment of Cancer(EORTC) studies to evaluate the role of pegylated liposomal doxorubicin(Caelyx) in the treatment of elderly patients with metastatic breastcancerfj]. Crit Rev Oncol Hematol, 2007,61 (1) :84-89.
  • 8Pierga JY,Fumoleau P,Brewer Y , et al. Efficacy and safety of singleagent capecitabine in pretreated metastatic breast cancer patients fromthe French compassionate use program[J]. Breast Cancer Res Treat,2004,88(2):117-129.
  • 9Wildiers H , Mauer M , Pallis A , et al. End points and trial design ingeriatric oncology research : a joint European organisation for researchand treatment of cancer-Alliance for Clinical Trials in Oncology-International Society Of Geriatric Oncology position article[J]. J Clin Oncol,2013,31(29):3711-3718.
  • 10Perez EA,Hillman DW,Dentchev T,et al. North central cancer treatmentgroup(NCCTG) N0432:phase II trial of docetaxel with capecitabine andbevacizumab as first-line chemotherapy for patients with metastatic breastcancer[J]. Ann Oncol,2010,21 (2) :269-274.

共引文献1355

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部